|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High-altitude illness显示文摘 | Buddha Basnyat David R Murdoch | 2003 | The Lancet . 2003 (9373)2003，，9373： | 2 |
| 2 | Hysteroscopic diagnosis of interstitial ectopic pregnancy显示文摘 | Reid P Buddha LL | 2004 | BJOG2004，111，1： | 1 |
| 3 | In virtro interaction of the Hiv protease inhibitor ritonavir with herbal constituents:changes in P-gp and CYP3A4 activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
| 4 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents:changes in P-gp and CYP3A4 activity 显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Tber2004，11，： | 1 |
| 5 | In vitro interaction of the HIVprotease inhibitor ritonavir with herbal constituents:changes in Pgp and CYP3A4 activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，： | 1 |
| 6 | Enteric (Typhoid) fever in travelers显示文摘 | Buddha B Ashish PM Mark DZ | 2005 | Clinical Infectious Diseases2005，41，10： | 1 |
| 7 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
| 8 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P- gp and CYP3A4 activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
| 9 | Hysteroscopic diagnosis of interstitial ec- topic pregnancy显示文摘 | REID P BUDDHA LL | 2004 | BJOG2004，111，2： | 1 |
| 10 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity 显示文摘 | Patel J Buddha B Dey S | 2004 | AmJ Ther2004，11，4： | 1 |
| 11 | High altitude cerebral and pulmonary edema显示文摘 | Buddha B | | 0，，04： | 1 |
| 12 | Hysteroscopic diagnosis of interstitial ectopic pregnancy 显示文摘 | Reid P Buddha LL | 2004 | B JOG2004，111，1： | 1 |
| 13 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal consti-tuents: changes in Pgp and CYP3A4 activity 显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
| 14 | In vitro Interaction of the HIV Protease Inhibitor Ritonavir with Herbal Constituents: Changes in P-gp and CYP3A4 Activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
| 15 | Complicationofurethralcatheterisation显示文摘 | BuddhaS | | 0，，9462： | 1 |
| 16 | Complication of urethral catheterisation显示文摘 | Buddha S | 2005 | Lancet2005，365，9462： | 1 |
| 17 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents : changes in P- gp and CYP3A4 activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
| 18 | In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents:changes in P-gp and CYP3A4 activity 显示文摘 | PATEL J BUDDHA B DEY S | 2004 | Am J Ther2004，11，4： | 1 |
| 19 | The role of active case finding in reducing patient incurred catastrophic costs for tuberculosis in Nepal显示文摘Background:The World Health Organization(WHO)End TB Strategy has established a milestone to reduce the number of tuberculosis(TB)-affected households facing catastrophic costs to zero by 2020.The role of active case finding(ACF)in reducing patient costs has not been determined globally.This study therefore aimed to compare costs incurred by TB patients diagnosed through ACF and passive case finding(PCF),and to determine the prevalence and intensity of patient-incurred catastrophic costs in Nepal.Methods:The study was conducted in two districts of Nepal:Bardiya and Pyuthan(Province No.5)between June and August 2018.One hundred patients were included in this study in a 1:1 ratio(PCF:ACF,25 consecutive ACF and 25 consecutive PCF patients in each district).The WHO TB patient costing tool was applied to collect information from patients or a member of their family regarding indirect and direct medical and non-medical costs.Catastrophic costs were calculated based on the proportion of patients with total costs exceeding 20%of their annual household income.The intensity of catastrophic costs was calculated using the positive overshoot method.The chi-square and Wilcoxon-Mann-Whitney tests were used to compare proportions and costs.Meanwhile,the Mantel Haenszel test was performed to assess the association between catastrophic costs and type of diagnosis.Results:Ninety-nine patients were interviewed(50 ACF and 49 PCF).Patients diagnosed through ACF incurred lower costs during the pre-treatment period(direct medical:USD 14 vs USD 32,P=0.001;direct non-medical:USD 3 vs USD 10,P=0.004;indirect,time loss:USD 4 vs USD 13,P<0.001).The cost of the pre-treatment and intensive phases combined was also lower for direct medical(USD 15 vs USD 34,P=0.002)and non-medical(USD 30 vs USD 54,P=0.022)costs among ACF patients.The prevalence of catastrophic direct costs was lower for ACF patients for all thresholds.A lower intensity of catastrophic costs was also documented for ACF patients,although the difference was not statistically significant.Conclusions:ACF can reduce patient-incurred costs substantially,contributing to the End TB Strategy target.Other synergistic policies,such as social protection,will also need to be implemented to reduce catastrophic costs to zero among TB-affected households. | Suman Chandra Gurung Kritika Dixit Bhola Rai Maxine Caws Puskar Raj Paudel Raghu Dhital Shraddha Acharya Gangaram Budhathoki Deepak Malla Jens W.Levy Job van Rest Knut Lonnroth Kerri Viney Andrew Ramsay Tom Wingfield Buddha Basnyat Anil Thapa Bertie Squire Duolao Wang Gokul Mishra Kashim Shah Anil Shrestha Noemia Teixeira de Siqueira-Filha | 2019 | Infectious Diseases of Poverty2019，8，6： | 1 |
| 20 | In vitro interactionof the HIV protease inhibitor ritonavir with herbalconstituents: changes in P-gp and CYP3A4 activity显示文摘 | Patel J Buddha B Dey S | 2004 | Am J Ther2004，11，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员